We are live on ! Find out more

Genmab

GMAB

Market cap $34.7B

56.49 USD

-0.80

1.4%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

56.14

-0.35

0.62%

1 day

-1.4%

5 days

41.79%

1 month

58.81%

3 months

98.07%

6 months

116.35%

Year to date

77.53%

1 year

95.13%

5 years

26.55%

10 years

210.73%

About: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Employees: 3,119

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.7%

Neutral 61.3%

Negative 0%

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops.

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab Stock Hits 52-Week High - Here's Why

Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting EGFR and LGR5.

Genmab Stock Hits 52-Week High - Here's Why

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1 positive head and neck squamous cell carcinoma (HNSCC), regardless of HPV status Genmab plans to engage global regulatory authorities and will submit full results for presentation at a future medical meeting Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial ( NCT06525220 ) evaluating petosemtamab , an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab versus pembrolizumab in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Based on the first interim analysis assessed by an independent data monitoring committee (IDMC), treatment with the petosemtamab combination demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) versus pembrolizumab [OS: HR 0.50 (95% CI, 0.37, 0.67); p

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Zacks Investment Research

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European Society for Medical Oncology Congress 2026, while securing a new clinical oncology partnership with Incyte Corporation (NASDAQ:INCY).

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Genmab Shares Jump After Positive Cancer Study Results

The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.

Genmab Shares Jump After Positive Cancer Study Results

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative disease Phase 3 program in 1L HNSCC is ongoing, with topline data anticipated later this year Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab for first-line (1L) treatment of recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC). In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%.

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors.

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

See News Rankings

Price charts implemented using Lightweight Charts™